Comprehensive, easy-to-understand information about this condition
How we create this content →The documentation on congenital stationary night blindness is limited primarily due to the rarity of the condition, which affects a small population worldwide. This rarity restricts the scope of systematic clinical studies and comprehensive genetic analyses. Additionally, the genetic basis of the condition is complex, and ongoing research is needed to fully characterize its phenotypic variability.
Patients with congenital stationary night blindness commonly experience myopia (80-99%), nyctalopia (80-99%), and reduced visual acuity (80-99%). Other clinical features may include strabismus (30-79%) and nystagmus (30-79%). Some individuals may present with congenital stationary night blindness with either normal or abnormal fundus findings, and a subset may have reduced amplitude of dark-adapted bright flash electroretinogram a-waves (5-29%).
To navigate your care effectively, consider consulting with a retinal specialist who has experience in hereditary retinal disorders. Genetic counseling may also be beneficial, especially given the involvement of multiple genes. While there are currently no patient organizations specifically identified for congenital stationary night blindness, resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov can provide valuable information and support. Additionally, inquire about participation in any available natural history studies or registries that may be established in the future.
Currently, there are five active clinical trials investigating various aspects of congenital stationary night blindness. These trials may explore potential interventions and management strategies. You can find more information about these trials by visiting ClinicalTrials.gov and searching for 'congenital stationary night blindness'.
Actionable guidance for navigating care for congenital stationary night blindness
To navigate your care effectively, consider consulting with a retinal specialist who has experience in hereditary retinal disorders. Genetic counseling may also be beneficial, especially given the involvement of multiple genes. While there are currently no patient organizations specifically identified for congenital stationary night blindness, resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov can provide valuable information and support. Additionally, inquire about participation in any available natural history studies or registries that may be established in the future.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
The documentation on congenital stationary night blindness is limited primarily due to the rarity of the condition, which affects a small population worldwide. This rarity restricts the scope of systematic clinical studies and comprehensive genetic analyses. Additionally, the genetic basis of the condition is complex, and ongoing research is needed to fully characterize its phenotypic variability.
Patients with congenital stationary night blindness commonly experience myopia (80-99%), nyctalopia (80-99%), and reduced visual acuity (80-99%). Other clinical features may include strabismus (30-79%) and nystagmus (30-79%). Some individuals may present with congenital stationary night blindness with either normal or abnormal fundus findings, and a subset may have reduced amplitude of dark-adapted bright flash electroretinogram a-waves (5-29%).
To navigate your care effectively, consider consulting with a retinal specialist who has experience in hereditary retinal disorders. Genetic counseling may also be beneficial, especially given the involvement of multiple genes. While there are currently no patient organizations specifically identified for congenital stationary night blindness, resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov can provide valuable information and support. Additionally, inquire about participation in any available natural history studies or registries that may be established in the future.
Currently, there are five active clinical trials investigating various aspects of congenital stationary night blindness. These trials may explore potential interventions and management strategies. You can find more information about these trials by visiting ClinicalTrials.gov and searching for 'congenital stationary night blindness'.
Actionable guidance for navigating care for congenital stationary night blindness
To navigate your care effectively, consider consulting with a retinal specialist who has experience in hereditary retinal disorders. Genetic counseling may also be beneficial, especially given the involvement of multiple genes. While there are currently no patient organizations specifically identified for congenital stationary night blindness, resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov can provide valuable information and support. Additionally, inquire about participation in any available natural history studies or registries that may be established in the future.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
The documentation on congenital stationary night blindness is limited primarily due to the rarity of the condition, which affects a small population worldwide. This rarity restricts the scope of systematic clinical studies and comprehensive genetic analyses. Additionally, the genetic basis of the condition is complex, and ongoing research is needed to fully characterize its phenotypic variability.
Patients with congenital stationary night blindness commonly experience myopia (80-99%), nyctalopia (80-99%), and reduced visual acuity (80-99%). Other clinical features may include strabismus (30-79%) and nystagmus (30-79%). Some individuals may present with congenital stationary night blindness with either normal or abnormal fundus findings, and a subset may have reduced amplitude of dark-adapted bright flash electroretinogram a-waves (5-29%).
To navigate your care effectively, consider consulting with a retinal specialist who has experience in hereditary retinal disorders. Genetic counseling may also be beneficial, especially given the involvement of multiple genes. While there are currently no patient organizations specifically identified for congenital stationary night blindness, resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov can provide valuable information and support. Additionally, inquire about participation in any available natural history studies or registries that may be established in the future.
Currently, there are five active clinical trials investigating various aspects of congenital stationary night blindness. These trials may explore potential interventions and management strategies. You can find more information about these trials by visiting ClinicalTrials.gov and searching for 'congenital stationary night blindness'.
Actionable guidance for navigating care for congenital stationary night blindness
To navigate your care effectively, consider consulting with a retinal specialist who has experience in hereditary retinal disorders. Genetic counseling may also be beneficial, especially given the involvement of multiple genes. While there are currently no patient organizations specifically identified for congenital stationary night blindness, resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov can provide valuable information and support. Additionally, inquire about participation in any available natural history studies or registries that may be established in the future.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 31, 2026
Consider asking your healthcare providers these condition-specific questions
European rare disease database
AI-Generated Content: This summary was generated using AI. Content has been fact-checked. Always consult with qualified healthcare providers for medical guidance.
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.